Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 9,145 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Breast Cancer
Interventions: HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 18
States / cities: San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more

Conditions: HIV Infections
Interventions: Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 96
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more

Conditions: Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions: Droxidopa, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 44
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more

Conditions: Multiple Sclerosis, Control Subjects, Autonomic Dysreflexia
Interventions: Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions: fluoroquinolone preprescription authorization, Control; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 5,871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more

Conditions: Aortic-valve Replacement
Interventions: 4D Cardiac CT Scan, LivaNova Bioprothetic Aortic Valve Implant; Diagnostic Test · Device
Lead sponsor: Corcym S.r.l; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Indianapolis, Indiana • Scarborough, Maine • Takoma Park, Maryland + 5 more

Conditions: Recurrent Pericarditis
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals (UK), Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Celiac Disease
Interventions: larazotide acetate, placebo, 900 mg gluten; Drug · Dietary Supplement
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Colorado Springs, Colorado • Chicago, Illinois + 14 more

Conditions: Onychomycosis
Interventions: MOB015B, Vehicle (Placebo Comparator); Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 33
States / cities: Birmingham, Alabama • Encinitas, California • Fremont, California + 30 more

Conditions: Non Small Cell Lung Cancer
Interventions: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose; Radiation
Lead sponsor: Cell>Point LLC; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • The Bronx, New York

Conditions: Indolent Non-Hodgkin's Lymphoma
Interventions: Arm A: Rituximab, Arm B: GA101; Biological
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 28
States / cities: Mobile, Alabama • Greenbrae, California • Savannah, Georgia + 25 more

Conditions: Unresectable Metastatic Colorectal Cancer
Interventions: ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Springdale, Arkansas • Duarte, California + 15 more

Conditions: Heart Failure
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 2,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 51
States / cities: Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more

Conditions: Chronic Constipation
Interventions: RM-131, Placebo; Drug
Lead sponsor: Motus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Liver Transplant Rejection
Interventions: Liver Transplant; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Interventions: capecitabine, irinotecan hydrochloride, oxaliplatin; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 115
States / cities: Hartford, Connecticut • Boise, Idaho • Cedar Rapids, Iowa + 76 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Patient-Specific Silicone Airway Stent; Device
Lead sponsor: VisionAir Solutions; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Clostridium Difficile Infection
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 17,535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 220
States / cities: Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more

Conditions: Back Pain
Interventions: Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine, Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Jacksonville, Florida • Baltimore, Maryland • Rochester, Minnesota + 2 more

Conditions: Soft Tissue Sarcoma
Interventions: TH-302 in Combination with Doxorubicin, Doxorubicin; Drug
Lead sponsor: Threshold Pharmaceuticals; Industry
Eligibility: 15 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 44
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 35 more

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Female only
Enrollment: 1,638 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
Interventions: nedosiran; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: Up to 11 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lupus Erythematosus, Systemic
Interventions: Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more

Search by objective public record fields.

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Deciphering Preserved Autonomic Function After Multiple Sclerosis

FQ Restriction for the Prevention of CDI

Behavior of Valve Leaflets Following Aortic Valve Implant

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

The TOGETHER Project - Liver

Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer

Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent

Clostridium Difficile Vaccine Efficacy Trial

Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus